8-K: Amarin Reports Q3 2024 Results: European Growth and Strong Cash Position Despite US Revenue Decline

Amarin reported a mixed third quarter with strong European growth and a solid cash position, but a significant decline in US revenue due to generic competition.

Summary

• Amarin announced its financial results for the third quarter of 2024, showing a total net revenue of $42.3 million, a 36% decrease compared to $66.1 million in the same period last year.
• The company's net product revenue also decreased by 36% to $41.9 million, primarily due to generic competition in the US and a change in CVS coverage.
• Despite the US challenges, European net product revenue increased significantly to $4.3 million, and Rest of World (RoW) net product revenue reached $6.9 million.
• VAZKEPA sales in Europe grew by 19% sequentially, driven mainly by Spain and the UK.
• Amarin maintained a strong cash position of $305.7 million, marking the ninth consecutive quarter of a positive or neutral cash balance.
• The company reported a net loss of $25.1 million for the quarter, or a loss of $0.06 per share.
• Operating expenses decreased by 18% to $41.4 million, reflecting cost optimization efforts.
• Amarin is committed to maintaining its public listing and is exploring options to resolve ongoing challenges.
• The company will host a virtual Analyst & Investor Day on November 14 to discuss the global opportunity for VASCEPA/VAZKEPA.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the significant revenue decline in the US, offset by positive growth in Europe and a strong cash position. The company is facing challenges but is also showing some resilience.

Positives

• Amarin has a strong cash position of $305.7 million.
• European sales of VAZKEPA are growing, with a 19% sequential increase in the third quarter.
• The company has secured national reimbursement for VAZKEPA in Portugal and Australia.
• Operating expenses have decreased by 18% due to cost optimization efforts.
• Amarin has maintained a +50% share of the IPE market in the US despite generic competition.
• The company has generated over $300 million in cash from the US business over the last nine quarters.

Negatives

• Total net revenue decreased by 36% year-over-year to $42.3 million.
• Net product revenue decreased by 36% to $41.9 million.
• US net product revenue decreased significantly to $30.6 million compared to $62.4 million in the same period last year.
• The company reported a net loss of $25.1 million for the quarter.
• Gross margin on net product revenue decreased to 38% from 44% in the same period last year, excluding a restructuring charge in Q3 2023, the gross margin was 64%.

Risks

• The company faces significant generic competition in the US market, impacting revenue.
• Amarin's US revenue has decreased substantially due to generic competition and changes in CVS coverage.
• The company is currently operating at a loss, with a net loss of $25.1 million for the quarter.
• There is uncertainty regarding the timing of an authorized generic launch in the US.
• The company's future performance is dependent on continued growth in Europe and other international markets.

Future Outlook

Amarin is focused on expanding in Europe, maintaining market share in the US, and maximizing cash generation from RoW markets. The company believes its current cash and investments are adequate to support operations for the foreseeable future.

Management Comments

• Aaron Berg, Amarin's President and CEO, stated that the company remains committed to evaluating all opportunities to maximize the value and impact of VASCEPA/VAZKEPA.
• Berg also emphasized the company's commitment to maintaining its public listing.

Industry Context

The pharmaceutical industry is facing increasing generic competition, particularly in the US market. Amarin's results reflect this trend, with a significant decline in US revenue due to generic entry. However, the company's growth in Europe and other international markets demonstrates the potential for global expansion.

Comparison to Industry Standards

• Amarin's 36% revenue decline in the US is significant and highlights the impact of generic competition, which is a common challenge for pharmaceutical companies after patent expiry.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) have faced similar challenges with generic entry impacting their branded drug sales.
• Amarin's European growth is a positive sign, but it needs to be compared to other companies launching in Europe, such as Novo Nordisk and Eli Lilly, to assess its relative success.
• The company's cash position of $305.7 million is relatively strong compared to other small to mid-cap pharmaceutical companies, providing a buffer against revenue declines.
• Amarin's focus on cost optimization is a common strategy for companies facing revenue pressures, similar to actions taken by companies like Perrigo and Bausch Health.

Stakeholder Impact

• Shareholders may be concerned about the significant revenue decline in the US and the net loss.
• Employees may be affected by cost optimization efforts.
• Customers in Europe will benefit from increased access to VAZKEPA.
• Suppliers may be impacted by changes in demand.
• Creditors will be reassured by the company's strong cash position.

Next Steps

• Amarin will continue to advance pricing and reimbursement efforts in Europe and other markets.
• The company will host a virtual Analyst & Investor Day on November 14.
• Amarin will continue to assess the potential optimal timing for an authorized generic launch in the US.

Key Dates

Keywords

Amarin, VASCEPA, VAZKEPA, Cardiovascular, Icosapent Ethyl, Revenue, Europe, Generic Competition, Cash Position, Reimbursement